Literature DB >> 19567997

[Hormones and osteoporosis update. Effect of angiotensin II on bone metabolism].

Hironori Nakagami1, Ryuichi Morishita.   

Abstract

Bone metabolism is closely regulated by hormones and cytokines, which have effects on both bone resorption and deposition. Since renin-angiotensin system (RAS) has been known to play an important role to regulate remodeling in several tissues, we focused on the potential role of RAS in bone metabolism. It is known that the receptors of angiotensin II are expressed in culture osteoclasts and osteoblasts, and angiotensin II induced the differentiation and activation of osteoclasts responsible for bone resorption. Of importance, angiotensin II significantly induced the expression of RANKL (receptor activator of NF-kappaB ligand) in osteoblasts, leading to the activation of osteoclasts, while these effects were completely blocked by an angiotensin II type 1 receptor blockade. In a rat ovariectomy model of estrogen deficiency, administration of angiotensin II accelerated the increase in TRAP activity, accompanied by a significant decrease in bone density and an increase in urinary deoxypyridinoline. As it has been known that osteoclast differentiation is regulated by a variety of hormones, local factors and inflammatory cytokines, such as IL-1 and TNF-alpha, RAS might also be involved in this autocrine system. Of importance, sub-analysis of recent clinical study demonstrated that the usage of angiotensin-converting enzyme inhibitors significantly reduced the fracture risk. RAS might be a novel target to treat the subgroups of hypertensive patients with osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19567997

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  4 in total

Review 1.  Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.

Authors:  Mahua Ghosh; Sumit R Majumdar
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

Review 2.  Heart failure as a risk factor for osteoporosis and fractures.

Authors:  Aloice O Aluoch; Ryan Jessee; Hani Habal; Melinda Garcia-Rosell; Rehan Shah; Guy Reed; Laura Carbone
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

Review 3.  Potential of RAS inhibition to improve metabolic bone disorders.

Authors:  Yoseph Gebru; Teng-Yue Diao; Hai Pan; Emmanuel Mukwaya; Yan Zhang
Journal:  Biomed Res Int       Date:  2013-07-22       Impact factor: 3.411

Review 4.  Bone in heart failure.

Authors:  Goran Loncar; Natasa Cvetinovic; Mitja Lainscak; Andjelka Isaković; Stephan von Haehling
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-02-22       Impact factor: 12.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.